If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down
OutcomeRx focuses on engaging with biotech companies to think through, structure, and manage value-based agreements
Payers are planning for an increasing number of gene therapies being approved by developing new coverage programs
Employers Medical Stop Loss for Specialty Rxs – Employers will continue to experience escalating specialty Rx costs. Effective but expensive non-substitutable products emerging from pharmaceutical manufacturers’ development pipelines will quickly and sharply drive both pharmacy and medical benefit year-over-year spending increases. Traditional risk management tools, like stop loss insurance policies are designed to mitigate risk […]